Galimedix Therapeutics Inc

Galimedix Therapeutics Inc. is a privately held company based in Kensington, Maryland. Employing 8 people, the company generates approximately $5.3 million in annual revenue. Galimedix Therapeutics focuses on developing innovative neuropharmaceutical drugs. Their research aims to create treatments that can halt or slow the progression of neurodegenerative diseases. The company's pipeline includes drugs targeting glaucoma, dry age-related macular degeneration (AMD), and Alzheimer's disease, all of which are leading causes of blindness. The company's development efforts are centered around creating first-in-class drugs, meaning they are pioneering new treatment approaches for these debilitating conditions. For more information, visit galimedix.com.